PUBLISHER: BCC Research | PRODUCT CODE: 1147908
PUBLISHER: BCC Research | PRODUCT CODE: 1147908
The global market for bronchitis treatments is estimated to grow from $5.8 billion in 2022 to $6.9 billion in 2027, with a compound annual growth rate (CAGR) of 3.5% for the period of 2022-2027.
The global market for Acute bronchitis treatments is estimated to grow from $2.4 billion in 2022 to $2.8 billion in 2027, with a CAGR of 3.7% for the period of 2022-2027.
The global market for Chronic bronchitis treatments is estimated to grow from $3.4 billion in 2022 to $4.0 billion in 2027, with a CAGR of 3.3% for the period of 2022-2027.
This study offers a global view of the treatment options for bronchitis in the market. This report analyzes and assesses the types of bronchitis, such as acute and chronic. It also provides information regarding different drugs classes, including antibiotics, anti-inflammatories and bronchodilators.
BCC Research analyzes and makes projections for each market and its segmentation, the regulatory environment, pipeline drugs and future aspects. The report also includes the impact of COVID-19 and profiles of leading companies in the bronchitis treatment market, including AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Cipla Inc., Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd.
The report covers the major markets of North America and Europe, as well as emerging markets, such as India, China, Japan and South Korea.